<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876301</url>
  </required_header>
  <id_info>
    <org_study_id>SPK-8011-301</org_study_id>
    <nct_id>NCT03876301</nct_id>
  </id_info>
  <brief_title>Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants</brief_title>
  <official_title>A Multi-Center, Observational Study in Males With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, observational study is to establish a dataset on the frequency
      of bleeding events, as well as other characteristics of bleeding events and FVIII infusions,
      in patients with clinically severe hemophilia A receiving prophylactic FVIII replacement
      therapy as standard of care. The data collected from this study may assist in providing
      baseline information for comparison to the Spark's investigational hemophilia A gene therapy
      in future Phase 3 studies.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeding events, annualized</measure>
    <time_frame>12 months</time_frame>
    <description>Annualized bleeding rate (ABR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose and total FVIIII consumption</measure>
    <time_frame>12 months</time_frame>
    <description>Total FVIII replacement therapy consumption and the corresponding dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized number of infusions (AIR)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of reported infusions over the study period</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <condition>Blood Coagulation Disorders, Inherited</condition>
  <condition>Coagulation Protein Disorders</condition>
  <condition>Hemophilia A</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Genetic Diseases, X-Linked</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Hemorrhagic Disorders</condition>
  <condition>Factor VIII Deficiency</condition>
  <arm_group>
    <arm_group_label>Observational Cohort</arm_group_label>
    <description>Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care FVIII Replacement therapy</intervention_name>
    <description>There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.</description>
    <arm_group_label>Observational Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males with clinically severe hemophilia A (i.e., ≤2% IU/dL FVIII activity level), who
        meet eligibility criteria for neutralizing antibody (NAb) to AAV-Spark200.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able and willing to provide written informed consent.

          2. Males ≥18 years of age.

          3. Clinically severe hemophilia A

          4. Previous exposure to FVIII therapy

          5. No prior history of hypersensitivity or anaphylaxis associated with an FVIII or
             intravenous immunoglobulin administration.

          6. No measurable inhibitor against FVIII

          7. Willing to participate and receive treatment in a future Spark hemophilia A gene
             therapy study.

        Exclusion Criteria:

          1. Documented active hepatitis B or C within the past 12 months of Screening

          2. Currently on antiviral therapy to treat hepatitis B or C;

          3. Documented significant liver disease within the past 6 months of Screening

          4. Have serological evidence of HIV-1 or HIV-2

          5. Anti-AAV-Spark 200 neutralizing titers ≥1:1

          6. Previously received SPK-8011;

          7. Previously dosed with any investigational or approved gene therapy product at any time
             or treated with an investigational drug within the last 12 weeks;

          8. Planned surgical procedure in the next 12 months requiring FVIII prophylactic
             treatment.

          9. Any history of chronic infection or other chronic disease, concurrent clinically
             significant major disease (such as liver abnormalities or type I diabetes) including
             active malignancy, except for non-melanoma skin cancer, any other condition or any
             other unspecified reasons that, in opinion of the Investigator or Sponsor, makes the
             participant unsuitable for participation and dosing in a future clinical study for
             Spark's hemophilia A gene therapy.

         10. Unable or unwilling to comply with the schedule of visits and/or study assessments
             described in the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Genetically male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Spencer K Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mississippi Center for Advanced Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bloodworks Northwest</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Austrailia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hematology/St. Paul's Hosptial</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V621Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University / Royal Prince Alfred Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor VIII</keyword>
  <keyword>Factor VIII Protein</keyword>
  <keyword>Recombinant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Coagulation Protein Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders, Inherited</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

